Vaccines
FDA advisers OK COVID-19 vaccines for youngest kids.
17 Jun, 2022 | 11:43h | UTCFDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP
See also: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press
Test-negative, case–control study: Effects of previous infection and vaccination on symptomatic omicron infections.
17 Jun, 2022 | 11:44h | UTCRelated:
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Two new studies show vaccination provides additional protection after Covid-19 infection.
Commentary on Twitter
A study in Qatar assessed the effectiveness of previous infection, vaccination, and both against symptomatic SARS-CoV-2 caused by omicron BA.1 and BA.2 and against severe, critical, or fatal #COVID19. https://t.co/bEVD3Y1sUn pic.twitter.com/Y38a0xxead
— NEJM (@NEJM) June 15, 2022
Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US veterans.
14 Jun, 2022 | 11:08h | UTC
Commentary on Twitter
1/
TODAY: We compared the safety of #COVID19 mRNA vaccines in the largest healthcare system in the US.TAKE-HOME MESSAGE: Both Moderna and Pfizer vaccines are quite safe. If interested in vaccination, you can confidently use whichever one is available.https://t.co/fFIlXwH5Qv
— Miguel Hernán (@_MiguelHernan) June 13, 2022
Maternal vaccination: a review of current evidence and recommendations.
3 Jun, 2022 | 11:40h | UTC
Commentary on Twitter
AJOG Expert Review: Maternal vaccination: a review of current evidence and recommendations – Placental transfer of IgG antibodies from maternal to fetal circulation https://t.co/yd3DQpwSoD pic.twitter.com/obicClLhzC
— AJOG (@AJOG_thegray) April 1, 2022
Network Meta-Analysis: Effectiveness of heterologous and homologous covid-19 vaccine regimens.
1 Jun, 2022 | 12:00h | UTCNews Release: Three doses of the same or mixed covid jabs work equally well against infections – BMJ
Commentary: Three jabs best for preventing Covid infections, global analysis finds – The Guardian
Analysis/Opinion: The unintended consequences of COVID-19 vaccine policy: “why mandates, passports and restrictions may cause more harm than good”.
30 May, 2022 | 11:46h | UTC
Commentary on Twitter (thread – click for more)
? Our paper on COVID-19 vaccine policy has been published??
We discuss 12 unintended consequences of mandates and passports across society
& argue that pandemic vaccine policies have caused more social harm than good
Read the paper: https://t.co/TeyTki0nWI pic.twitter.com/BRJQRURbUc
— Kevin Bardosh (@KevinBardosh) May 26, 2022
Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds.
27 May, 2022 | 12:04h | UTCCommentary: Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds – The BMJ
Cohort Study: Protection and waning of natural and hybrid immunity to SARS-CoV-2.
26 May, 2022 | 11:07h | UTCProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Commentary on Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022
Study Commentary: Long COVID risk falls only slightly after vaccination, huge study shows.
26 May, 2022 | 11:25h | UTCCommentary: Long COVID risk falls only slightly after vaccination, huge study shows – Nature
Original Study: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine
Commentary from the author on Twitter (thread – click for more)
The latest from our team in @NatureMedicine
Does vaccination protect from #LongCovid?
Vaccines modestly reduce but do not eliminate risk of Long Covid @VAResearch @vahsrd @WUSTLmed @WUSTLnews @VREFSTL@Biostayan @BCBowe https://t.co/UEexmL8svS
A thread ?
— Ziyad Al-Aly, MD (@zalaly) May 25, 2022
Test-negative, case–control study: effectiveness of homologous and heterologous Covid-19 boosters against Omicron.
26 May, 2022 | 10:59h | UTC
Effectiveness of CoronaVac in children 3 to 5 years during the SARS-CoV-2 Omicron outbreak in Chile.
25 May, 2022 | 11:42h | UTC
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.
25 May, 2022 | 11:34h | UTCRelated recommendations:
RCT: Safety and immunogenicity of heterologous boost immunization with an orally administered aerosolized Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults.
23 May, 2022 | 01:54h | UTC
Commentary on Twitter
Mix-and-match typically refers to different shots. Here's a randomized trial of shots and an oral vaccine that ameliorates the immune responsehttps://t.co/FFWHEwS37Y @LancetRespirMed pic.twitter.com/JZyvrxCalS
— Eric Topol (@EricTopol) May 21, 2022
WHO validates 11th vaccine for COVID-19.
20 May, 2022 | 11:16h | UTCWHO validates 11th vaccine for COVID-19 – World Health Organization
Commentary on Twitter
WHO issued an emergency use listing for CONVIDECIA, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of #COVID19 vaccines validated by WHO https://t.co/QdpHiasT2p pic.twitter.com/2B54FwiNDl
— World Health Organization (WHO) (@WHO) May 19, 2022
Covid-19: Second boosters may benefit at-risk groups but have “minimal” impact for others, says WHO.
20 May, 2022 | 11:08h | UTCOriginal Statement: Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 – World Health Organization
Related recommendations:
RCT: Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age.
12 May, 2022 | 10:22h | UTC
Commentary on Twitter
Two 50-μg doses of mRNA-1273 vaccine were found to be safe and effective in inducing immune responses and preventing Covid-19 in children 6 to 11 years of age. https://t.co/A5SBK4zK6E pic.twitter.com/7x4JgOwK57
— NEJM (@NEJM) May 11, 2022
Phase 2 RCT: A fourth dose of an mRNA Covid-19 vaccine increases cellular and humoral immunity against SARS-CoV-2.
11 May, 2022 | 11:14h | UTCCommentaries:
What a second booster dose of mRNA COVID-19 vaccines tells us – The Lancet Infectious Diseases
Covid: Fourth-dose jab trial shows good boost – BBC
Commentary on Twitter (thread – click for more)
The results of the @CovBoost fourth dose booster substudy are now online in @TheLancetInfDis
We demonstrated fourth doses of covid vaccines were safe and well tolerated and boost antibody levels above their peak following a third dosehttps://t.co/zGi0iNCAcL
— Alasdair Munro (@apsmunro) May 10, 2022
M-A: Interventions to improve immunization coverage among children and adolescents.
11 May, 2022 | 10:45h | UTC
Kids get limited COVID protection from world’s most popular vaccines – “First analyses of two Chinese-made vaccines in young children show that the shots do provide 60–65% effectiveness against hospitalization”.
10 May, 2022 | 11:04h | UTCKids get limited COVID protection from world’s most popular vaccines – Nature
Studies show promise for 2 new COVID vaccine platforms.
9 May, 2022 | 02:12h | UTCCommentary: Studies show promise for 2 new COVID vaccine platforms – CIDRAP
Editorial: Does the World Still Need New Covid-19 Vaccines?
Commentaries on Twitter
Efficacy of a plant-based vaccine with adjuvant was 69.5% against symptomatic #COVID19 and 78.8% against moderate-to-severe disease. https://t.co/WH54QWCBdg pic.twitter.com/BiEYpJUD7D
— NEJM (@NEJM) May 4, 2022
ZF2001 vaccine has 87% efficacy against critical or severe #COVID19 for at least 6 months after full vaccination and was safe in large cohort of adults. #IDTwitter https://t.co/wsG0AXqI4Y pic.twitter.com/45fqwVrz9a
— NEJM (@NEJM) May 4, 2022
M-A of randomized trials: association of influenza vaccination with cardiovascular risk.
3 May, 2022 | 10:58h | UTCAssociation of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis – JAMA Network Open
Commentary on Twitter
In this meta-analysis, seasonal flu vaccine was associated with a 34% reduced risk of major adverse cardiovascular events in 1 year, with the biggest difference in patients with recent acute coronary syndrome. @WCHResearch @PMunkCardiacCtr https://t.co/SPrXNfMQJS
— JAMA Network Open (@JAMANetworkOpen) April 29, 2022
Review: Understanding vaccine safety and the roles of the FDA and the CDC.
29 Apr, 2022 | 11:13h | UTCUnderstanding Vaccine Safety and the Roles of the FDA and the CDC – New England Journal of Medicine
Commentary on Twitter
Development and public acceptance of vaccines are crucial for disease control. Cody Meissner, M.D., reviews the process of evaluating vaccine safety and efficacy and factors that advisory bodies consider in making recommendations. https://t.co/ITqpGthoac pic.twitter.com/HTkyAaWvDO
— NEJM (@NEJM) April 28, 2022
RCT: BCG vaccine is not effective in reducing healthcare worker absenteeism in COVID-19 pandemic.
29 Apr, 2022 | 11:05h | UTC
Commentary on Twitter
BCG-CORONA RCT? @CMIJournal @MarcBonten
BCG-vaccination of health care worker exposed to #COVID19 patients did NOT reduce unplanned absenteeism nor documented COVID-19 #IDTwitter #MedEd #TwitteRx #MedTwitter https://t.co/yqnpmuy5Y8— Antibiotic Steward Bassam Ghanem?? (@ABsteward) April 28, 2022
Phase 2b trial: Prefusion F protein–based respiratory syncytial virus immunization in pregnancy.
28 Apr, 2022 | 08:09h | UTCPrefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: RSV Prefusion F Protein-Based Immunization Studied in Pregnancy – HealthDay
Commentary on Twitter
In pregnant women, RSVpreF vaccine elicited neutralizing antibody responses with efficient transplacental transfer and without evident safety concerns. https://t.co/r8oktZmBZQ pic.twitter.com/UE7ffxYJW6
— NEJM (@NEJM) April 27, 2022
Cohort Study: Incidence of Guillain-Barré syndrome after Covid-19 vaccination in the vaccine safety datalink.
27 Apr, 2022 | 08:03h | UTC
Commentary on Twitter
This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV
— JAMA Network Open (@JAMANetworkOpen) April 26, 2022